key: cord-0728171-p6s6oarl authors: Alene, Kefyalew Addis; Wangdi, Kinley; Colquhoun, Samantha; Chani, Kudakwashe; Islam, Tauhid; Rahevar, Kalpeshsinh; Morishita, Fukushi; Byrne, Anthony; Clark, Justin; Viney, Kerri title: Tuberculosis related disability: a systematic review and meta-analysis date: 2021-09-09 journal: BMC Med DOI: 10.1186/s12916-021-02063-9 sha: ae0febedb5c3aba3df18b6dd00158f0499548c37 doc_id: 728171 cord_uid: p6s6oarl BACKGROUND: The sustainable development goals aim to improve health for all by 2030. They incorporate ambitious goals regarding tuberculosis (TB), which may be a significant cause of disability, yet to be quantified. Therefore, we aimed to quantify the prevalence and types of TB-related disabilities. METHODS: We performed a systematic review of TB-related disabilities. The pooled prevalence of disabilities was calculated using the inverse variance heterogeneity model. The maps of the proportions of common types of disabilities by country income level were created. RESULTS: We included a total of 131 studies (217,475 patients) that were conducted in 49 countries. The most common type of disabilities were mental health disorders (23.1%), respiratory impairment (20.7%), musculoskeletal impairment (17.1%), hearing impairment (14.5%), visual impairment (9.8%), renal impairment (5.7%), and neurological impairment (1.6%). The prevalence of respiratory impairment (61.2%) and mental health disorders (42.0%) was highest in low-income countries while neurological impairment was highest in lower middle-income countries (25.6%). Drug-resistant TB was associated with respiratory (58.7%), neurological (37.2%), and hearing impairments (25.0%) and mental health disorders (26.0%), respectively. CONCLUSIONS: TB-related disabilities were frequently reported. More uniform reporting tools for TB-related disability and further research to better quantify and mitigate it are urgently needed. PROSPERO REGISTRATION NUMBER: CRD42019147488 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-02063-9. Tuberculosis (TB) is a significant cause of death and disability worldwide, killing approximately 1.2 million people of an estimated 10 million new cases in 2019 [1] . While disability is a recognized consequence of TB, the prevalence of TB-related disability has not been estimated. Disability includes any impairment or activity limitation as well as participation restriction [2] . Globally, low-and middle-income countries account for almost two-thirds of years lived with a disability [3] . While not well reported in the literature, TB can result in either temporary or permanent disability, arising from the disease process itself or side effects related to TB treatment, particularly related to second-line medicines used to treat drug-resistant (DR)-TB. TB service interruptions in high burden TB countries due to the ongoing COVID-19 pandemic may increase TB-related morbidity, disability, and mortality [4, 5] . Physical disabilities related to TB vary according to the bodily site affected by TB. For example, people with a history of pulmonary TB may suffer from a range of long-lasting respiratory-related sequelae such as impaired lung function (obstructive, restrictive, reduced diffusing capacity, or reduced lung volumes), chronic obstructive pulmonary disease (COPD), bronchiectasis, aspergillosis, pulmonary hypertension, or pulmonary fibrosis [6] [7] [8] [9] . The global burden of COPD as a consequence of TB has recently been estimated to be 5.9 million disability-adjusted life years (DALYs) [10] . TB of the nervous system, affecting the meninges, brain, spinal cord, or cranial and peripheral nerves, can cause severe irreversible disability [11] . For example, spinal TB can result in paraparesis and quadriparesis due to spinal deformity and damage of the neural structures, often leading to permanent physical disabilities [12] . Some disabilities arise due to organ or tissue destruction in the host from TB disease, while others are a result of adverse effects of treatment. TB treatment is effective, prevents death, and limits disability, but certain medications have side effects which may result in temporary or permanent disability. Previous studies have demonstrated an increased prevalence of visual disturbance and hearing loss among people previously treated for DR-TB [13, 14] . However, some of the medicines that were used in these studies such as kanamycin and capreomycin are no longer recommended by the World Health Organization [15] . Mental health disorders may also be more prevalent among TB survivors than the general population [16, 17] . Mood disorders including anxiety and depression may be associated with TB disease, TB treatment, or factors not directly related to TB. Whereas the long treatment duration of 9-20 months for DR-TB results in disruptions to usual work, family, and social activities, TB patients may also be subjected to stigma and discrimination due to cultural norms or beliefs associated with TB, which can cause or exacerbate mental health disorders. Although not well studied, the effect of TB treatment on the cognitive development of children and adolescents as a result of disruption to schooling may also be significant [18] . Despite a growing interest in the long-term sequelae associated with TB, the global prevalence of TB-related disability is currently unknown. Describing the spectrum and prevalence of TB-related disabilities is crucial to inform service provision and policy making in countries where TB is common and to mitigate future disability in patients being treated for TB. In this systematic review, we aimed to quantify the global prevalence and types of TB-related disabilities. We performed a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [19] . We searched PubMed, Embase, and Web of Science databases for studies that reported on permanent disability associated with TB, using prespecified search terms. We checked the reference lists of included papers for additional relevant references and performed a backwards and forwards citation search. Our search strategy (Additional file 1) was developed by a senior research information specialist (JC) and respiratory physician (AB), both with extensive experience in conducting systematic reviews in health and medicine. The screening of articles by title and abstract was carried out independently by three researchers (KW, KAA and SC) in Rayyan [20] . Full-text papers were then independently screened by four researchers (KW, KAA, CK, and SC) using eligibility criteria described below. Disagreement was resolved through discussion and consensus. Participants were people in all age groups with any type of TB (pulmonary and extra pulmonary TB, new and relapse, drug-sensitive (DS), and DR-TB), from all regions and countries. Our intervention of interest was TB treatment based on national and international guidelines for TB (for both DS and DR-TB). However, studies without a specific intervention (i.e., for those who did not specifically report that the patients were on TB treatment but which clearly stated that the patients had been diagnosed with TB) were also included. Our outcomes of interest were the prevalence of TB patients who developed a permanent form of disability, detected or reported after TB diagnosis, and where TB disease or TB treatment may have contributed to the disability. Our definitions of disability are included in Additional file 2. We included observational studies (e.g., crosssectional, case-control, or cohort studies) and experimental epidemiological studies that reported data from the year 2000 until July 2019. Our research question in the PICO (Population, Intervention, Comparator, Outcome) format is included in Table 1 . We excluded studies that reported temporary disabilities (for example, a mental health disorder attributable to an adverse event during treatment that was resolved by a change of medication). Descriptive epidemiological studies were also excluded (case reports and case series) as were other systematic reviews; scientific correspondence, posters, and conference abstracts; studies conducted in animals; and historical data reported before the year 2000. Data were extracted into a Microsoft Excel 2016 spreadsheet (Microsoft, Redmond, Washington, USA) by four researchers (KW, SC, CK, and KA). The data extraction spreadsheet was pilot tested and refined before extraction. The lists of variables included in the data extraction tool are available in the Additional file 3. All included articles were assessed for quality using a modified Ottawa Newcastle quality assessment scoring tool [21] . Meta-analysis was performed to estimate the pooled prevalence of each form of disability using the inverse variance heterogeneity model. Stratified analyses were conducted by country income-level and TB type, separately for each disability when two or more studies were available on the outcome of interest (see Additional file 4 for details). This review was registered in the Prospective Register of Systematic Reviews (PROSPERO, CRD42019147488). Ethical approval was not sought for this study as it includes an analysis of secondary data. The search strategy yielded 3485 unique publications, 619 articles remained after the title and abstract screening. After full-text review, 124 publications (comprising 164 datasets) were included in the review. A backward and forward citation search found 410 publications, of which 53 were not identified in the original search; seven of these were subsequently included in the final analysis. Some studies reported more than one type of disability, and thus a total of 175 datasets (217,475 patients) from 131 unique studies were included (Fig. 1) . The characteristics of the included studies are presented in Table 2 . The included studies were conducted in 49 countries. The majority of studies were conducted in India 24.6% (n=43) followed by South Africa 9.7% (n= 17) and Brazil 5.1% (n=9). The mean age of study participants was 36.7 years (±16.3) and 59.6% of cases were male. More than one-third of studies (39%, n=68) reported that their study population had DS-TB, while 29.1% (n=51) included patients with DR-TB. The site of TB disease was not reported in 41.1% of studies (n=72), while 28.6% (n=50) and 16.0% (n=28) included patients with pulmonary TB (PTB) and extra-pulmonary TB (EPTB), respectively. More than half of the studies (52.9%, n=90) reported that disabilities were diagnosed during TB treatment. The review showed that the most common type of disabilities were mental health disorders (23.1%), respiratory impairment (20.7%), musculoskeletal impairment (17.1%), hearing impairment (14.5%), visual impairment (9.8%), renal impairment (5.7%), and neurological impairment (1.6%). There was large heterogeneity in the prevalence of disability. Two variables, namely country income level and type of TB, were identified as the source of heterogeneity across all types of disability and therefore were used as the primary variables of stratification. Table 3 shows the number of studies and the prevalence of disabilities associated with TB, stratified by country income level. A total of 43 studies reported respiratory impairment. Nearly two-thirds of patients in LICs (61.2%) and just over half in LMICs (56.1%) experienced some form of respiratory impairment. The prevalence was low among HICs (14.9%) and UMICs (15.3%) (Fig. 2) . Similarly, the highest prevalence of patients with mental health disorders was observed among patients in LICs (42%) followed by LMICs (31.3%), UMICs (30.6%), and HICs (4.3%; Fig. 3 ). The prevalence of patients with neurological function impairment was highest in LMICs (25.6%) and UMICs (15.9%) and lowest in LICs (5.9%) and HICs (1.3%; Fig. 4 ). The highest prevalence of TB patients who experienced hearing impairment (59.1%) was reported in HICs and UMICs 27.4% and 11.0% and 5% were reported from LMICs and LICs, respectively (Fig. 5 ). Among patients with DS-TB, the prevalence of respiratory impairment was 33.1% while 21.9% of patients reported mental disorders, 12.5% reported neurological impairment, 11.9% reported visual impairment, and 2.3% reported hearing impairment (Table 3) . Among patients with DR-TB, the prevalence of patients reporting respiratory impairment was 58.7% while 26% reported mental disorder, 15% reported hearing impairment, 4.6% reported neurological impairment, and 2.7% reported visual impairment. Studies including patients with DS-TB and DR-TB (with the inclusion of an injectable agent) reported that 37.2% of patients had a neurological impairment, 33.1% had respiratory impairment, 25% had a hearing impairment, and 20.7% had a mental disorder, with none of the studies reporting visual impairment. Neurological impairment was also high in studies which included DS-TB and DR-TB patients who did not receive an injectable agent (28.5%). Additional information on disabilities by HIV status, timing of disability diagnosis, and study design is provided in Table 3 . The quality of included studies was low to moderate overall, with a median score of 5 points (the maximum score is 9 points). Of the included 131 studies, only 11 studies had a score of 8 or 9 points, regarded as highquality studies. The remaining studies scored 7 points or less, with 28 of them scoring 4 points or lower, classified as a low-quality study. Additional file 5: Table S1 presents the results of the quality assessment scores and Additional file 6: Table S2 includes the quality assessment tools. This systematic review attempts to quantify the prevalence and types of TB-related disabilities. We found a substantial burden of TB-related disabilities, with four common types: (1) respiratory impairment, (2) hearing impairment, (3) mental health disorders, and (4) neurological impairment. Respiratory impairment was the most common disability identified in this review. There was inconsistency in how respiratory impairment was diagnosed and reported. However, the prevalence of respiratory impairment was heterogeneous when stratified by country income level. The highest prevalence was reported in LICs (61.2%) and LMICs (56.1%). This may correlate with the high burden of TB in these countries, difficulties in accessing health care, or poverty. Poverty is widely recognized as a risk factor for TB and may also result in respiratory impairment [149] [150] [151] . High rates of respiratory impairment in LICs and LMICs may also be partially explained by low levels of health service coverage [152, 153] . High coverage of essential health services, including early access to TB diagnosis, treatment, and care, with appropriate monitoring of patients while on treatment, may minimize the long-term sequelae and disabilities associated with TB [154] . Other causes of lung diseases such as cigarette smoking and air pollution (indoor and outdoor) may contribute to the high prevalence of respiratory disabilities observed in LICs and LMICs [155, 156] . One systematic review reported a positive association between a history of TB treatment and chronic respiratory diseases, including COPD and bronchiectasis [157] . This association was much stronger in non-smokers and in high TB incidence countries [157] . WHO has recommended an integrated strategy to manage respiratory patients in primary health care settings with a focus on priority respiratory diseases, particularly TB [158] . Respiratory impairment was also higher among those with DR-TB. We found an almost twofold increase in the prevalence of respiratory impairment among patients with DR-TB (58.7%), compared with DS-TB (33.1%). This is consistent with previous research demonstrating a greater prevalence of COPD among successfully treated MDR-TB patients compared to patients treated for DS-TB and community controls [159] . This supports the notion of integration of DR-TB programs with respiratory health care. Importantly, there are currently no international guidelines that recommend screening for respiratory impairment after TB treatment, although there is interest in this from several clinical and public health groups [160] . Post TB treatment respiratory care including outpatient pulmonary rehabilitation may be beneficial for some TB survivors, especially in countries with a high burden of DR-TB. DR-TB treatment completion may be a possible entry point into these programs, where they exist. Similarly, national TB programs may want to consider how they provide incentives and enablers to patients with DR-TB so that they can monitor patients closely, or consider how they can link patients to services such as social protection schemes and disability services. Both are key interventions included in the End TB Strategy [161] and in many national TB strategic plans. While incentives and enablers are frequently provided, linkages to social protection and disability services are less frequently implemented. Mental health disorders have historically been neglected as a focus in TB research [162] [163] [164] . Our review revealed a high prevalence of mental health disorders such as depression, anxiety and mood disorders, posttraumatic stress disorder (PTSD), and psychosis among TB patients, with substantial variation by country income level. The highest prevalence of mental health disorders was reported in LICs (42%) and the lowest prevalence in HICs (4.3%). Although our study did not include comparison data for the general population, based on other literature, we note that the prevalence of mental health disorders among TB patients in our review is higher than the prevalence of mental health disorders among the general population [165] . The prevalence of mental health disorders in our review was similar to the prevalence of mental health disorders among people with other chronic diseases such as HIV infection [166] , diabetes mellitus [167] , and cancer [168] , from previous systematic reviews. The relationship between mental health disorders and TB may be specific to the socioeconomic context or other factors such as health care affordability. Also, it has been well documented that TB patients and their families frequently face stigma and discrimination [169, 170] . Depression, anxiety, and other mental health disorders could be connected to this experience of stigma, loss of identity, ongoing symptoms, and the socioeconomic consequences of TB [171] . Mental health disorders can contribute to an inability to complete TB treatment and subsequently to disability [172] . The high burden of mental health disorders associated with TB suggests that additional efforts are required to improve TB care [173, 174] . We found hearing impairment (hearing loss) among TB survivors to be common, particularly among patients with DR-TB or after taking second-line TB medications. The prevalence of hearing impairment among patients with DR-TB was 15%, which is seven times higher than the prevalence of hearing impairment among patients with DS-TB (2.3%). The disorder of hearing in patients on second-line TB medications, such as the aminoglycosides (i.e., amikacin, kanamycin, and streptomycin), is common [36, 175] . A previously published review of aminoglycoside-induced hearing impairment among TB patients also reported a high incidence of ototoxicity (7-90%) [176] . The appropriate use of TB medications should help health care providers prevent hearing loss among patients. Therefore, WHO now recommends MDR-TB treatment without the aminoglycosides [174] . We found that the prevalence of hearing impairment was higher in HICs (59%) and UMICs (27%) compared to LMICS (11%) and LICs (5%). This could be due to differences in diagnostic methods or the availability of diagnostic (auditory) equipment in HICs and UMICs to assess hearing impairment [22] . Ascertainment and/or publication bias may also be relevant here as few studies were available from LMICs and LICs. Different audiological assessment methods were used for the diagnosis of hearing impairment in our included studies, including otoscopy, pure tone audiometry, otoacoustic product emissions, and automated auditory brainstem response testing [22] . Audiometry was not always available for all patients to assess hearing impairment at baseline, during treatment, and after completion of TB treatment, to quantify the timeline of hearing loss. As a result, it was not possible to establish the main cause of hearing loss among patients with TB in this review. However the prevalence of hearing impairment in this review (14.6%) is substantially higher than the global estimates of people with disabling hearing loss in 2018 (6.1%) [177] . It is worthwhile to highlight the definition of hearing impairment as defined in this review and the local estimates may be different [174] . The hearing impairment could have a considerable effect on the quality of life, work, and social relationships [22, 178] . Therefore, hearing assessments for TB patients receiving aminoglycosides should be included as part of the management package. In addition, rehabilitation packages for those with hearing impairment should be offered routinely [22, 179] . The patients on the second-line injectable drugs reported more than 37% neurological impairment compared to patients without an injectable TB medication (28.5%). The most common types of TB-related neurological impairments reported in our review were paraplegia, hemiplegia, cranial nerve palsies, peripheral neuropathy, hydrocephalus, and visual loss. These neurological impairments were permanent and irreversible and therefore have long-term functional, social, economic, and psychological consequences for affected patients [180, 181] . TB of the central nervous system accounts for 5-10% of all EPTB globally, with TB meningitis, intracranial TB, and spinal TB being some of the most severe forms of TB [182, 183] . TB of the spine (or Pott's disease) affects the intervertebral discs and adjacent vertebrae, which may result in vertebral collapse, destruction, skeletal deformities, and disability [184, 185] . In addition, compression of the spinal cord and/or nerves may result in neurologic deficits [186] . To reduce the burden of neurological deficits in children from TB meningitis, improving BCG vaccination coverage in countries with low coverage of BCG is an important intervention [187] . The findings of our review suggest a pressing need to prevent or screen for TB-related disability among TB patients and survivors. Strategies to prevent or reduce TBrelated disability include improving access to health care, promoting early TB diagnosis, appropriate use of TB medications, and providing training for health care workers. Adverse event monitoring, pharmacovigilance, therapeutic drug monitoring, and providing incentives and enablers for patients for treatment adherence or compliance and report adverse events should be introduced as part of the TB treatment package. After TB treatment, care including follow-up and continued monitoring for possible disability or sequelae should be initiated urgently. This systematic review has several limitations. There was large heterogeneity in the prevalence of disabilities across studies which limited our ability to conduct a meta-analysis for all type of disabilities. There was also a large amount of missing data noted in our studies; for example, nearly 25% of studies had missing data for the type of TB, and HIV status was missing for 50% of the included studies. Therefore, we were unable to include these variables in the main analysis to explore the heterogeneity in these variables. In addition, in some studies, it was not possible to determine the temporal nature of the disability (i.e., whether disability occurred before, during, or after TB treatment) because the data were collected from studies that used cross-sectional study designs. For example, more than half of the papers (53%) included in the mental health impairment were crosssectional studies. We may have some misclassification of disability for this reason. However, we attempted to explain this by conducting subgroup analysis. Moreover, we did not include studies published in languages other than English; 63 studies were excluded for this reason. Therefore, we may be missing important studies, from high TB and DR-TB burden countries such as China, the Russian Federation, and others. Lastly, as with all meta-analyses, the validity of the results is limited by the conduct and reporting of the studies from which the data were extracted and pooled. TB-related disabilities are common affecting different body parts. The burden of TB-related disability varied by the income of country, susceptibility of TB, and secondline TB drugs. The commonly reported disabilities were respiratory impairment, hearing impairment, mental health disorders, and neurological impairment. Therefore, measures to prevent and reduce TB-related disabilities should be introduced urgently as a comprehensive TB treatment package. The online version contains supplementary material available at https://doi. org/10.1186/s12916-021-02063-9. Additional file 1. Search strategies. Additional file 2. Definitions of disability in our study. Additional file 3. Variables included in the data extraction tools. Additional file 4. Data analysis. Additional file 5: Table S1 . Quality assessment tools. Additional file 6: Table S2 . Quality assessment article summary table. Thank you for ANU and WHO WPRO for providing the opportunity to undertake this collaborative project. Authors' contributions KAA, KW, and KV conceived the study, which was refined by SC, KC, TI, KR, FM, AB, and JC. JC conducted the literature search. KAA, KW, SC, and KC screened the full-text papers and extracted the data. KAA run the analysis. KAA, KW, SC, KC, and KV drafted the manuscript, and all authors provided input into revisions and approved the final draft for submission. This review was funded by the End TB Unit, World Health Organization Regional Office for the Western Pacific, under an Agreement for Performance of Work contract, with Australian National University. In-kind support was provided by the Australian National University, Curtin University, the Telethon Kids Institute, The University of Sydney, and Bond University. KV is supported by a Sidney Sax Early Career Fellowship from the Australian National Health and Medical Research Council (NHMRC), Canberra ACT, Australia (GNT1121611). SC is supported by NHMRC ISER Centre for Research Excellence grant (APP1107393). KAA is funded by NHMRC Investigator Grant (APP1196549). The funders provided no input into the undertaking or reporting of the research. A list of included studies has been made available. The study protocol can be accessed on PROSPERO (CRD42019147488). International classification of functioning, disability and health Impact of the COVID-19 pandemic on tuberculosis control: an overview The potential impact of COVID-19-related disruption on tuberculosis burden Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review Tuberculosis associates with both airflow obstruction and low lung function: BOLD results Pulmonary tuberculosis: the day after Burden of non-communicable diseases from infectious causes in 2017: a modelling study Central nervous system tuberculosis in HIV-infected patients: clinical and radiographic findings Spinal tuberculosis: a comprehensive review for the modern spine surgeon Rising burden of visual and auditory disability in patients after tuberculosis therapy in Peruvian slums Visual morbidity and ocular complications in presumed intraocular tuberculosis: an analysis of 354 cases from a non-endemic population Comorbidities between tuberculosis and common mental disorders: a scoping review of epidemiological patterns and person-centred care interventions from low-to-middle income and BRICS countries A review of the interplay between tuberculosis and mental health Assessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative study Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Rayyan-a web and mobile app for systematic reviews Newcastle-Ottawa quality assessment scale cohort studies Hearing loss in patients on treatment for drug-resistant tuberculosis Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa The occurrence of auditory dysfunction in children with TB receiving ototoxic medication at a TB hospital in South Africa Comparing amikacin and kanamycin-induced hearing loss in multidrugresistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort An audiological profile of patients infected with multi-drug resistant tuberculosis at a district hospital in Audiological testing for ototoxicity monitoring in adults with tuberculosis in state hospitals in Gauteng Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger Poor outcomes in recurrent tuberculosis: more than just drug resistance? Nephrotoxicity and ototoxic symptoms of injectable second-line antitubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study Adverse events related to multidrug-resistant tuberculosis treatment Evaluation of hearing in patients with multiresistant tuberculosis The course of spinal tuberculosis (Pott disease): results of the multinational, multicentre Backbone-2 study Hearing impairment in patients with tuberculosis from Northeast Brazil The importance of audiometric monitoring in patients with multidrug-resistant tuberculosis Improvements in physical and mental health among HIV-infected patients treated for TB in Thailand Profile of adverse drug reactions in drug resistant tuberculosis from Punjab Outcome of tuberculous meningitis in children: the first comprehensive retrospective cohort study in Indonesia Corticosteroids for managing tuberculous meningitis Audiological evaluation of patients taking kanamycin for multidrug resistant tuberculosis Spectrum of intracranial tuberculosis Need of the hour': early diagnosis and management of multidrug resistant tuberculosis of the spine: an analysis of 30 patients from a "high multidrug resistant tuberculosis burden" country Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital Efficacy of utilising patient self-report of auditory complaints to monitor aminoglycoside ototoxicity Post treatment sequelae of multidrug resistant tuberculosis patients Treatment outcomes and adverse events from a standardized multidrugresistant tuberculosis regimen in a rural setting in Angola Depression comorbidity among patients with tuberculosis in a university teaching hospital outpatient clinic in Nigeria The synergy between TB and HIV co-infection on perceived stigma in Ethiopia Prevalence of depression in tuberculosis patients in comparison with non-tuberculosis family contacts visiting the DOTS clinic in a Nigerian tertiary care hospital and its correlation with disease pattern Frequency and correlates of anxiety and mood disorders among TB-and HIV-infected Zambians Prevalence of post-traumatic stress symptoms and associated factors in tuberculosis (TB), TB retreatment and/or TB-HIV co-infected primary public health-care patients in three districts in South Africa Prevalence of suicidal behaviour & associated factors among tuberculosis patients in public primary care in South Africa Emotional distress in Angolan patients with several types of tuberculosis Prevalence and correlates of depression and anxiety among patients with tuberculosis at WolaitaSodo University Hospital and Sodo Health Center, WolaitaSodo, South Ethiopia, Cross sectional study Prevalence and correlates of depressive symptoms in adult patients with pulmonary tuberculosis in the Southwest Region of Cameroon Burden and presentation of depression among newly diagnosed individuals with TB in primary care settings in Ethiopia Major depression and household food insecurity among individuals with multidrug-resistant tuberculosis (MDR-TB) in South Africa Prevalence and associated factors of depression among tuberculosis patients in Eastern Ethiopia Co-morbid anxiety and depression among pulmonary tuberculosis patients Osteoarticular tuberculosis in Tehran, Iran: a 2-year study Effect of pharmacist-led patient education on management of depression in drug resistance tuberculosis patients using cycloserine. A prospective study Frequency of depression in tuberculosis patients and its association with various sociodemographic factors Prevalence of complications of tuberculous meningitis in patients presenting to paediatric department Assessment of anxiety, depression, loneliness and stigmatization in patients with tuberculosis Clinical presentations and outcomes related to tuberculosis in children younger than 2 years of age in Catalonia Health-related quality of life, depression and anxiety in hospitalized patients with tuberculosis Prevalence of depression among patients with presumptive pulmonary tuberculosis in Rio de Janeiro, Brazil Psychiatric morbidity in patients of pulmonary tuberculosis-an observational study Psychological morbidity and illness perception among patients receiving treatment for tuberculosis in a tertiary care centre in Sri Lanka Effect of duration tuberculosis treatment on depression symptoms level of tuberculosis patients in Karang Bahagia. Prim Health Care Bekasi Depression among tuberculosis patients attending a DOTS centre in a rural area of Delhi: a cross-sectional study Prevalence and associated factors of depressive state among pulmonary tuberculosis patients in Manila, The Philippines Anti-tuberculosis druginduced liver injury in Shanghai: validation of Hy's Law Perceived stigma and depression in initially diagnosed pulmonary tuberculosis patients Survey on tuberculosis patients in rural areas in China: tracing the role of stigma in psychological distress Prevalence of depressive symptoms and related risk factors among patients with tuberculosis in China: a multistage cross-sectional study Extrapulmonary tuberculosis in children: a study of 41 cases Spinal tuberculosis: a retrospective chart review Tuberculosis of and around the ankle Effect of delayed diagnosis on severity of Pott's disease Tuberculosis of the elbow region in pediatric age group-experiences from a single centre Tuberculous meningitis diagnosis and treatment in adults: a series of 189 suspected cases Experiences in management of Pott's paraplegia and paraparesis in medical wards of Usmanu Danfodiyo University Teaching Hospital Pott's disease in children Criteria indicating morbidity in tuberculous meningitis Presentation and outcome of tuberculous meningitis among children: experiences from a tertiary children's hospital Surgical management of contiguous multilevel thoracolumbar tuberculous spondylitis Evaluation of twelve patients with tuberculous meningitis Tuberculous meningitis in Denmark: a review of 50 cases Tuberculous meningitis in children and adults: a 10-year retrospective comparative analysis Think central nervous system tuberculosis, also in low-risk children: a Danish nationwide survey Evaluation of voice disorders in patients with active laryngeal tuberculosis The epidemiology of spinal tuberculosis in the United States: an analysis of 2002-2011 data Prognostic clinical variables in childhood tuberculous meningitis: an experience from Mumbai Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis Clinical profile of tuberculous meningitis in kashmir valley-the Indian subcontinent Neurological complications of miliary tuberculosis Tuberculous meningitis in adults: a prospective study at a tertiary referral centre in Sri Lanka Morbidity and mortality at five years after initiating Category I treatment among patients with new sputum smear positive pulmonary tuberculosis Tuberculosis and the risk of ischemic stroke: a 3-year follow-up study Risk assessment of the outcome for cerebral infarction in tuberculous meningitis Structural deficits and cognitive impairment in tuberculous meningitis Association between tuberculosis and Parkinson disease: a nationwide, populationbased cohort study Lung functions among patients with pulmonary tuberculosis in Dar es Salaam -a cross-sectional study Adverse effects and choice between the injectable agents amikacin and capreomycin in multidrug-resistant tuberculosis Urinary tuberculosis with renal failure: challenges in management Radiological changes post-lymph node enucleation for airway obstruction in children with pulmonary tuberculosis Post-tuberculous lung function impairment in a tuberculosis reference clinic in Cameroon Chronic lung disease in adult recurrent tuberculosis survivors in Zimbabwe: a cohort study Prevalence of lung function impairment in cured pulmonary tuberculosis patients in Cotonou, Benin Chronic lung disease and a history of tuberculosis (post-tuberculosis lung disease): Clinical features and in-hospital outcomes in a resource-limited setting with a high HIV burden Post-tuberculous chronic obstructive pulmonary disease Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis -limitations for the underlying COPD detection Pulmonary function and respiratory health after successful treatment of drug-resistant tuberculosis Functional profile of patients with tuberculosis sequelae in a university hospital Bronchoscopic findings in patients with pulmonary tuberculosis Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis The functional assessment of patients with pulmonary multidrugresistant tuberculosis Chronic symptoms and pulmonary dysfunction in post-tuberculosis Brazilian patients Pulmonary tuberculosis, impaired lung function, disability and quality of life in a high-burden setting Radiological evaluation of chest in abdominal tuberculosis HIV, multidrug-resistant TB and depressive symptoms: when three conditions collide Risk factors associated with development of pulmonary impairment after tuberculosis Correlation of chest computed tomography findings with dyspnea and lung functions in post-tubercular sequelae Evaluation of tuberculosisassociated chronic obstructive pulmonary disease at a tertiary care hospital: a case-control study A study of clinical profile of cases of MDR-TB and evaluation of challenges faced in initiation of second line Anti tuberculosis treatment for MDR-TB cases admitted in drug resistance tuberculosis center Clinico-radiologic and spirometric profile of an Indian population with post-tuberculous obstructive airway disease Pulmonary functions' assessment in posttuberculosis cases by spirometry: obstructive pattern is predominant and needs cautious evaluation in all treated cases irrespective of symptoms Sequelae of pulmonary multidrug-resistant tuberculosis at the completion of treatment Assessment of lung function in successfully treated tuberculosis reveals high burden of ventilatory defects and COPD Lung function in patients with chronic airflow obstruction due to tuberculous destroyed lung Prior TB, smoking, and airflow obstruction a cross-sectional analysis of the Guangzhou Biobank Cohort Study The association between airflow obstruction and radiologic change by tuberculosis Clinical characteristics of patients with tuberculosis-destroyed lung Pulmonary impairment in tuberculosis survivors: The Korean National Health and Nutrition Examination Survey Risk factors for pulmonary arterial hypertension in patients with tuberculosis-destroyed lungs and their clinical characteristics compared with patients with chronic obstructive pulmonary disease Emphysema and bronchiectasis in COPD patients with previous pulmonary tuberculosis: computed tomography features and clinical implications History of pulmonary tuberculosis affects the severity and clinical outcomes of COPD Adjunctive use of prednisolone in the treatment of free-flowing tuberculous pleural effusion: A retrospective cohort study Pulmonary tuberculosis: the day after Clinical features and prognostic factors in presumed ocular tuberculosis The collaborative ocular tuberculosis study (cots), an international study of the clinical evaluation and management of ocular tuberculosis at 25 centres: Report 1 on clinical assessment and management outcomes Degree, duration, and causes of visual impairment in eyes affected with ocular tuberculosis Risk of cataract for people with tuberculosis: Results from a population-based cohort study High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho Hand and wrist tuberculosis in paediatric patientsour experience in 44 patients Tuberculosis and poverty Tuberculosis and poverty: why are the poor at greater risk in India? Global Monitoring Report: World Health Organization and International Bank for Reconstruction and Development / The World Bank A comprehensive assessment of universal health coverage in 111 countries: a retrospective observational study Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries Tuberculosis and chronic respiratory disease: a systematic review Practical approach to lung health (PAL): A primary health care strategy for the integrated management of respiratory conditions in people five years of age and over: World Health Organization Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis Posttuberculosis lung health: perspectives from the First International Symposium Implementing the end TB strategy: the essentials: World Health Organization Tuberculosis: an opportunity to integrate mental health services in primary care in low-resource settings Tuberculosis and mental health in the Asia-Pacific Integrating tuberculosis and mental health services: global receptivity of national tuberculosis program directors The global prevalence of common mental disorders: a systematic review and metaanalysis 1980-2013 Prevalence of anxiety in adults with diabetes: a systematic review Epidemiology of depression and diabetes: a systematic review The prevalence of long-term symptoms of depression and anxiety after breast cancer treatment: a systematic review Tuberculosis stigma as a social determinant of health: a systematic mapping review of research in low incidence countries Tuberculosis control and elimination 2010-50: cure, care, and social development Self, identity, stress, and mental health. Handbook of the sociology of mental health Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis: World Health Organization Treatment -Drug-Resistant Tuberculosis Treatment: WHO Hearing impairment in patients with tuberculosis from Northeast Brazil Aminoglycoside-induced hearing deficits-a review of cochlear ototoxicity Prevention of hearing loss in patients with multidrug-resistant tuberculosis A case report: the first successful cochlear implant in Uganda Peripheral neuropathy in persons with tuberculosis Pulmonary tuberculosis, impaired lung function, disability and quality of life in a high-burden setting Guidelines for clinical and operational management of drug-resistant tuberculosis The global neurological burden of tuberculosis Spinal tuberculosis: a review Spinal cord involvement in tuberculous meningitis Spinal tuberculosis: a review BCG vaccine protection against TB infection among children older than 5 years in close contact with an infectious adult TB case Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations